



HOSTED BY THE WORKING GROUPS OF THE STOP TB PARTNERSHIP

4th Annual New Tools Summit

Monday, 16 November 2026 · Windsor Marapendi Hotel, Rio de Janeiro, Brazil

Agenda *(draft)*

Registration and coffee

08:45 – 09:15

Welcome and opening remarks

09:15 – 09:30

Opening remarks

Lucica Ditiu, Stop TB Partnership

Community lessons and importance of access as a priority for new tools to end TB

Maxime Lunga, Club des Amis Damien (DRC) and TB survivor

Session 1 · Innovations in Treatment

09:30 – 12:00

Welcome and introduction from the Working Group on New TB Drugs (WGND)

Zaid Tanvir, TB Alliance and WGND Secretariat

New drug regimens and trial updates from research consortia and sponsors

UNITE4TB (Jodie Schildkraut) · US CDC Tuberculosis Trials Consortium
Otsuka Pharmaceutical Co. Ltd (Irina Kontsevaya) · Aurum Institute (Bob Wallis)
Gates Medical Research Institute

Coffee break

10:30 – 10:50

New drug regimens and trial updates from research consortia and sponsors (continued)

TB Alliance · GlaxoSmithKline · SMART4TB (Payam Nahid)

Wrap-up from WGND

Zaid Tanvir

Remarks from the Global Drug-resistant TB Initiative (GDI)

Ignacio Monedero-Recuero, Action Damien and GDI Chair

Drug-resistant TB in war and complex emergencies: novelties in implementation and unmet research priorities

Ignacio Monedero-Recuero

Emerging bedaquiline resistance: Reasons and lessons for the introduction of novel TB drugs

Cheng Yuan Chiang, The International Union Against TB and Lung Disease, and GDI Core Group

Wrap-up from GDI

Ignacio Monedero-Recuero

Lunch (provided)

12:00 – 13:00

Session 2 · Innovations in Diagnosis

13:00 – 15:00

Welcome and introduction from the New Diagnostics Working Group (NDWG) and the Global Laboratory Initiative (GLI)

Daniela Cirillo, San Raffaele Scientific Institute and NDWG Co-Chair

Leen Rigouts, Institute of Tropical Medicine Antwerp and GLI Core Group

Experience with early programmatic implementation of TB near-point of care (NPOC) molecular tests in Cameroon

Valerie Flore Donkeng Donfack, Cameroon Pasteur and GLI Core Group

From innovation to impact: Engaging private providers in the introduction and scale-up of new TB tools

Mohammed Yassin, Global Fund and PPM Working Group Chair

Priorities in the diagnosis and treatment of childhood and adolescent TB

Chishala Chabala, University of Zambia and Vice-Chair, Childhood and Adolescent TB Working Group (recorded)

State of the art: pipeline of new diagnostics

Seda Yerlikaya, Heidelberg University

Innovator showcase: short presentations by innovating companies + panel Q&A

Ustar, Co-Dx, Pluslife, Coyote, Genes2Me, Genoscreen, Qiagen, Fluxus, Level 42 AI

Wrap-up from NDWG and GLI

Daniela Cirillo and Leen Rigouts

Coffee break

15:00 – 15:20

Session 3 · Innovations in Prevention**END TB TRANSMISSION INITIATIVE (ETTi): INFECTION PREVENTION AND CONTROL (IPC)**

15:20 – 16:10

Welcome and introduction from ETTi

Jerod Scholten, ETTi Core Group Member

Air filtration, purification and air quality sampling/warning advances

Paul Jensen, Final Approach Inc. and ETTi Secretariat

Advances in use of Far Germicidal Ultraviolet 222 nm light for reducing TB and other respiratory infections

Ed Nardell, Harvard Medical School

Case study in Peru on TB & respiratory infection prevention with architectural innovations

Isabel Milagros Ochoa Delgado, Peru National Institute of Child Health

Panel Q&A

All presenters

Wrap-up from ETTi

Jerod Scholten

Bio-break

16:10 – 16:20

WORKING GROUP ON NEW TB VACCINES (WGNV)

16:20 – 17:35

Welcome and introduction from WGNV

David Lewinsohn, Oregon Health & Science University and WGNV Chair

TB Vaccine R&D: State of the Field**Upstream and preclinical research**

David Lewinsohn

Clinical development of new TB vaccines

Monde Muyoyeta, Centre for Infectious Disease Research in Zambia

Advancing the next generation of TB vaccines**Phase 1 vaccine candidates led by high-burden countries**

LipovaxinS4-EAH (Neni Nurainy, PT BioPharma (Persero) [recorded])

Ad5-105K (Ruijie Wang, CanSino [recorded])

RH119 (Yu Pang, Beijing Chest Hospital)

How do we identify and advance the next generation of TB vaccine clinical candidates?

Alexander Schmidt, Gates Foundation

Preparing for implementation**TB Vaccine Accelerator updates on country preparedness and readiness**

Birgitte Giersing, World Health Organization

Wrap-up from WGNV**Closing**

17:35 – 17:40